cute decompensated heart failure is a major health problem that is associated with several million hospitalizations worldwide each year, poor short-term outcomes, and high costs. [1] [2] [3] Despite the magnitude of the problem, rates of early death and rehospitalization have not improved over the past several decades. 3 Nesiritide, a recombinant B-type natriuretic peptide (BNP) with vasodilatory properties, [4] [5] [6] [7] was approved in 2001 for use in patients with acute heart failure on the basis of studies showing a reduction in pulmonary-capillary wedge pressure and improvement in dyspnea at 3 hours. 5, 6, 8 However, subsequent pooled analyses of data from small, randomized trials suggested that nesiritide, as compared with placebo, was associated with a rate of worsening renal function that was increased by a factor of 1.5 and a rate of early death that was increased by a factor of 1.8, although the confidence intervals associated with these estimates were wide. 9, 10 An independent panel convened to evaluate this issue recommended that a large clinical trial be conducted to answer the question of whether nesiritide is effective and safe. 11 Accordingly, the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial was designed to evaluate the effect of nesiritide, in addition to standard care, on rates of selfreported dyspnea at 6 and 24 hours, rehospitalization for heart failure or death from any cause at 30 days, and renal dysfunction.
Me thods

Study Design and Oversight
The ASCEND-HF was a randomized, double-blind, placebo-controlled trial of nesiritide in addition to standard care. The study design has been published elsewhere, 12 and the study protocol is available with the full text of this article at NEJM.org. The trial was conducted from May 2007 through August 2010 at 398 centers throughout the world. The study was approved by each participating center's ethics committee or institutional review board, and all participants provided written informed consent. Research sites in North America were managed by a consortium of academic research organizations that included the Canadian VIGOUR Centre, the Cleveland Clinic's C5 Research Group, the Duke Clinical Research Institute, the Henry Ford Coordinating Center, and the Jefferson Coordinating Center for Clinical Research.
The Duke Clinical Research Institute performed study-data processing and statistical analyses, and the Duke Clinical Research Institute, a network of academic research organizations, and Johnson & Johnson Pharmaceutical Research and Development managed the study at the participating sites. The executive committee was responsible for the trial design, and the steering committee supervised patient recruitment and clinical management of the trial. Before the database was locked, only the drug-distribution group and the data and safety monitoring board maintained the code for group assignments. The manuscript was initially drafted by the academic authors, and it was written independently of the sponsor by the executive and steering committees. The sponsor was allowed to comment on the manuscript before submission, but all final decisions were made by the executive committee. An independent data and safety monitoring board met after every 1000 patients had been recruited, and statistical analyses were conducted by Frontier Science and Technology Research Foundation independently of the sponsor.
After the database was locked, the sponsor and executive committee were made aware of potential quality issues at one site that had randomly assigned 121 patients to a study group. The site used duplicate copies of electrocardiographic tracings as data for more than one subject or subject visit date. Additional statistical analyses performed to determine whether other data were potentially affected did not identify any other data abnormalities. Since this information was obtained after the database was locked and the overall study results were unblinded, and sensitivity analyses censoring data from this site showed no material change in the efficacy or safety analyses or conclusions, the decision was made not to alter the data sets in the primary analysis. The first author vouches for the completeness and accuracy of the data and the analyses as well as the fidelity of the study to the protocol.
Study Patients
Patients were eligible to participate in the study if they were hospitalized for heart failure occurring within 24 hours before they received their first intravenous treatment for heart failure or if they had received a diagnosis of acute decompensated heart failure less than 48 hours after hospitalization for another cause and underwent randomization within 24 hours after intravenous treatment for heart failure. Additional criteria at the time of randomization included the following: dyspnea at rest or with minimal activity, one or more accompanying signs (respiratory rate ≥20 breaths per minute or pulmonary congestion or edema with rales one third of the way or more up the lung fields), and one or more objective measures of heart failure (evidence of congestion or edema on chest radiography, a BNP level ≥400 pg per milliliter or an N-terminal pro-BNP level ≥1000 pg per milliliter, pulmonary-capillary wedge pressure >20 mm Hg, or left ventricular ejection fraction <40% in the previous 12 months). 12 Key exclusion criteria were a high risk of hypotension (systolic pressure <100 mm Hg or 110 mm Hg with the use of intravenous nitroglycerin), other contraindications for vasodilators, treatment with dobutamine (at a dose ≥5 μg per kilogram of body weight per minute), treatment with milrinone or levosimendan within the previous 30 days, persistent uncontrolled hypertension, acute coronary syndrome, normal level of BNP or N-terminal pro-BNP, severe pulmonary disease, end-stage renal disease during receipt of renalreplacement therapy, and clinically significant anemia. Complete eligibility criteria are described elsewhere 12 and in the study protocol.
Study-Drug Administration
Eligible patients were randomly assigned in a 1:1 ratio to receive nesiritide or placebo. All participants received standard therapies, including diuretics, morphine, and other vasoactive medications, as determined by the investigator with the guidance of a standard-of-care manual. 13 After a recommended but optional intravenous bolus of nesiritide, at a dose of 2 μg per kilogram (administered at the discretion of the investigator), nesiritide was administered as a continuous infusion of 0.010 μg per kilogram per minute for 24 hours or more for up to 7 days.
End Points
The study had two coprimary end points: the change in self-reported dyspnea 6 and 24 hours after study-drug initiation and the composite end point of rehospitalization for heart failure and death from any cause during the period from randomization to day 30. Dyspnea was measured with the use of a self-reported 7-point categorical Likert scale, ranging from "markedly better" to "markedly worse," as compared with the degree of dyspnea present at the start time of study-drug administration. Rehospitalization and fatal events within 30 days after randomization were reviewed and categorized by an independent, blinded clinical-events committee at the University of Glasgow. The following criteria were required for hospitalization events to be classified as due to heart failure: typical clinical manifestations of worsening heart failure and the addition of (or increase in) treatment specifically for worsening heart failure with an intravenous pharmacologic agent, or mechanical or surgical intervention or ultrafiltration, hemofiltration, or dialysis specifically for management of persistent or worsening heart failure. Hospitalized patients who remained in the hospital at 30 days because of heart failure were counted as being rehospitalized for heart failure in the analysis of the coprimary end point.
Secondary end points included self-reported overall well-being, measured 6 and 24 hours after study-drug initiation with the use of the 7-point Likert scale, the composite end point of persistent or worsening heart failure and death from any cause during the period from randomization through hospital discharge (index hospitalization), the number of days alive and out of the hospital through day 30, and the composite end point of death from cardiovascular causes and rehospitalization due to cardiovascular causes from randomization through day 30.
Safety end points included death from any cause during the period from randomization through day 30; death from cardiovascular causes; sudden death from cardiac causes through day 30; need for renal replacement therapy (defined by >25% decrease from the baseline estimated glomerular filtration rate, calculated with the use of the simplified Modification of Diet in Renal Disease equation) at any time from study-drug initiation through day 30; and the occurrence of investigator-reported hypotension relative to the participant's baseline blood pressure through hospital discharge or 10 days after study-drug initiation, whichever occurred first.
Statistical Analysis
Calculation of the sample size was based on the composite end point of rehospitalization for heart failure or death from any cause through day 30. The planned enrollment of 7000 patients was estimated to provide 89% power, with the use of the chisquare test and a two-sided alpha level of 0.045, to detect a difference between groups, assuming an event rate of 11.4% in the nesiritide group and an event rate of 14.0% in the placebo group (relative risk reduction, 18.6%). For the dyspnea end point, this sample size was estimated to provide 99% power, with the use of the Wilcoxon rank-sum test and a two-sided alpha level of 0.0025, to detect an effect size of 0.543 between the nesiritide and placebo groups (translating to a 54.3% probability that a patient receiving nesiritide would report a better outcome than a patient receiving placebo).
The differences between study drugs with respect to the binary composite end point and the renal end points were estimated with the use of the Cochran-Mantel-Haenszel test, stratified according to region. Hypotension was compared between treatment groups with the use of a chi-square test. Ordinal variables (scores on the Likert scale) were compared with the use of the van Elteren test, 14 with adjustment for region. The numbers of days that patients were alive and out of the hospital were assessed with the use of analysis of variance, with adjustment for region.
Differing views on the part of regulators in the United States and Europe regarding the primacy of end points led to the creation of two analysis plans. The primary analysis plan tested the coprimary end points with the use of a Bonferroni approach. The composite of rehospitalization for heart failure and death from any cause at day 30 was tested at the 0.045 significance level, and the assessments of dyspnea at 6 and 24 hours were tested at the 0.005 level with the use of the Hochberg method. The dyspnea end point was considered significant if the P values were ≤0.005 at both 6 and 24 hours, or if either of the two P values was ≤0.0025. If the coprimary composite efficacy end point was significant at the specified level of 0.045, the analysis of the secondary end points was to be performed sequentially at an alpha level of 0.045 with the use of closed-testing principles (or 0.05 as specified by the European Medicines Agency).
The European Medicines Agency considered the dyspnea end points to be primary efficacy end points and rehospitalization for heart failure (combined with mortality) to be a secondary end point, so that Bonferroni correction was not part of the analysis plan required by that agency. Thus, for the regulatory purposes of the European Medicines Agency, the primary end points were dyspnea alone at 6 and 24 hours, and these end points were tested at an alpha level of 0.05 with the use of the Hochberg method, with statistical significance indicated by a P value of 0.05 or less for both the 6-and 24-hour assessments or by a P value of 0.025 or less for one of the assessments.
The following prespecified subgroup analyses were performed to evaluate the homogeneity of treatment effects on primary and secondary end points: geographic region; use or nonuse of a study-drug bolus; use or nonuse of an inotropic agent, intravenous vasodilator, or intravenous nitroglycerin at randomization; use or nonuse of a diuretic from the onset of the qualifying episode of heart failure through randomization; sex; age; race or ethnic group; baseline renal function, ejection fraction, and systolic blood pressure; and presence or absence of a history of coronary artery disease or diabetes mellitus.
Primary efficacy analyses and safety analyses were performed for the modified intention-to-treat population, defined as all randomly assigned participants who received any amount of study medication. Efficacy analyses were conducted according to randomized treatment assignment; safety analyses were conducted according to actual treatment received. All statistical analyses were performed with the use of SAS software, version 9.2 (SAS Institute).
R e sult s
Patient Population
From May 2007 through August 2010, a total of 7141 patients underwent randomization at 398 sites in North America, Europe, Latin America, and the Asia-Pacific region. Of these participants, 7007 (98%) received a study drug (3496 patients assigned to nesiritide and 3511 assigned to placebo) and were included in the modified intention-to-treat analysis (Fig. S1 in the Supplementary Appendix, available at NEJM.org). The study groups were well balanced and similar in all respects (Table 1) and similar to the intention-to-treat group.
Coprimary End Points
The distribution of patient-reported assessments of dyspnea at 6 and 24 hours is shown in Figure 1A . Although a small increase in the number of patients reporting improvement in dyspnea was observed at both the 6-and 24-hour time points, this finding did not meet the prespecified criteria for significance.
Rehospitalization for heart failure or death from any cause at 30 days (Fig. 1B) cause or rehospitalization for heart failure of 0.93 (95% CI, 0.80 to 1.08) (Fig. S2 in the Supplementary Appendix).
Secondary End Points
Self-reported overall well-being at 6 and 24 hours did not differ significantly between the groups (Fig. S3 in the Supplementary Appendix). In addition, no significant differences between the groups were seen with respect to the secondary end points of rehospitalization for cardiovascular causes or death from cardiovascular causes, or total days alive and out of the hospital at 30 days. The end point of persistent or worsening heart failure or death from any cause from randomization through hospital discharge (index hospitalization) was also similar between the nesiritide and placebo groups (4.2% and 4.8%, respectively; absolute difference, −0.6 percentage points; 95% CI, −1.5 to 0.5) ( Table 2 ).
Safety End Points
There was no significant difference between the groups with respect to the rate of death from any cause at 30 days (Table 2) . A total of 126 participants who received nesiritide (3.6%) and 141 participants who received placebo (4.0%) died within 30 days after randomization (absolute difference, −0.4 percentage points; 95% CI, −1.3 to 0.5).
There was no significant difference between the nesiritide group and the placebo group with respect to the proportion of patients with renal impairment at any time from randomization through day 30 (31.4% and 29.5%, respectively; odds ratio with nesiritide, 1.09; 95% CI, 0.98 to 1.21) ( Table  2) , regardless of the degree of baseline renal insufficiency. The proportion of patients with an episode of hypotension was significantly greater in the nesiritide group than in the placebo group (26.6% vs. 15.3%, P<0.001), with a median systolic pressure of 80 mm Hg (interquartile range, 70 to 87) during the episode among patients who received nesiritide and 80 mm Hg (interquartile range, 70 to 85) among patients who received placebo. Both asymptomatic hypotension and symptomatic hypotension occurred more often in patients who received nesiritide than in patients who received placebo (asymptomatic, 21.4% vs. 12.4%; symptomatic, 7.2% vs. 4.0%; P<0.001 for both comparisons) ( Table 2) . No significant differences in serious adverse events were observed (Table S1 in the Supplementary Appendix)
Subgroup Analyses
The coprimary outcome of rehospitalization for heart failure or death from any cause within 30 days was consistent across prespecified subgroups (Fig. 2) . Likewise, the results of the subgroup analysis for the coprimary end point of self-reported dyspnea were consistent across prespecified groups (Fig. 3) .
Discussion
In this trial, the use of nesiritide in patients with acute decompensated heart failure neither increased nor decreased the incidence of death or rehospitalization for heart failure at 30 days. Selfreported dyspnea at 6 and 24 hours was marginally improved when nesiritide was added to conventional therapy, but this finding did not meet prespecified criteria for statistical significance. Nesiritide thus cannot be recommended in the broad population of patients with acute decompensated heart failure represented by the study population in this trial.
The effect of nesiritide on the dyspnea end point in this trial was consistent with the findings of the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC; ClinicalTrials.gov number, NCT00270374) trial that formed the basis for the Food and Drug Administration's approval of nesiritide. The VMAC study included only 498 patients, and the significant effect on dyspnea at 3 hours was observed for nesiritide as compared with placebo, but this effect was similar to that of intravenous nitroglycerin, and no significant effect was detected at 24 hours. 6 The VMAC protocol encouraged the withholding of additional therapy unless it was required because of worsening symptoms. Analyses in the current trial showed † Data shown are percentage-point differences, with the exception of data for >25% decrease in estimated GFR from study-drug initiation, for which the data shown are odds ratios.
a small effect of nesiritide on dyspnea in most of the participants who received other therapies before and during study-drug infusion; these findings are consistent with the VMAC study results showing a smaller effect of nesiritide as compared with an active control of nitroglycerin, in contrast to nesiritide versus placebo. In this era of comparative effectiveness assessments, we know little about the comparative effectiveness of standard treatments for acute heart failure, including diuretics, [15] [16] [17] [18] [19] morphine, 20 inotropic agents, 21 oxygen, 22 and vasodilators such as nitroglycerin. 15 The development of nesiritide poses fundamental questions about the manner in which therapies are developed and assessed. Because nesiritide was not studied in a major outcome trial early in its life cycle, both patients and physicians lacked an appropriate understanding of the proper role of the drug in practice. Our findings also underscore the fact that systematic overviews with small numbers of events can yield unreliable estimates of the balance of benefits and risks, and interpretation of the data is confounded by these imprecise estimates. An updated systematic overview of 30-day mortality data in trials involving patients with acute decompensated heart failure that compared nesiritide with placebo or other control agents showed no adverse effect of nesiritide on survival 9 (Fig. S4 in the Supplementary Appendix) .
This international trial was subject to differing regulatory views regarding the most appropriate analysis plan. According to the primary statistical analysis plan, the effect of nesiritide on dyspnea, although numerically superior, was not significant, whereas analyses required by the European Medicines Agency resulted in a significant result -a divergence that shows the need for better harmonization of regulatory views. 23 Regardless of which statistical and regulatory plan is considered, the supporting analyses point to a conclusion that is consistent with previous findings. Data on race, systolic pressure, ejection fraction (EF), estimated glomerular filtration rate (GFR), and coronary artery disease were not available for some patients. Several limitations of this trial should be noted. First, the trial primarily addressed safety concerns; thus, the design was intentionally permissive so that the study population would include a broad range of patients with acute decompensated heart failure. Second, the evaluation of dyspnea remains rudimentary, despite the number of studies that have used the 7-point Likert scale, and the minimal clinically important difference between treated and untreated groups remains unclear. 24 Third, the clinical-event rate was lower than expected, and in future trials, samples approaching 10,000 subjects would be required to provide greater certainty regarding clinically relevant end points.
In summary, in this study, nesiritide neither increased nor decreased the rate of death and rehospitalization. The observed effect of nesiritide on dyspnea in this trial was small (and not significant) with the coadministration of other therapies that relieve congestion. Nesiritide was not associated with worsened renal function, but it was associated with an increase in the rate of hypotension. In hindsight, nesiritide was approved and swiftly adopted in the United States because of its perceived large benefit in relieving dyspnea and congestion, and then its use markedly decreased because of published meta-analyses reporting a detrimental effect on survival and renal function. 25 Our study showed that neither belief was accurate. The results of this trial highlight the urgent need for rigorously designed trials with adequate power to provide reliable estimates that can replace incomplete or inadequate evidence as a basis for therapeutic decisions.
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